The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 21 of the 28 sources its claims cite were checked for support.
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Open accessAbstract
Summ a r yTransfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) are severe monogenic diseases with severe and potentially life-threatening manifestations.BCL11A is a transcription factor that represses γ-globin expression and fetal hemoglobin in erythroid cells.We performed electroporation of CD34+ hematopoietic stem and progenitor cells obtained from healthy donors, with CRISPR-Cas9 targeting the BCL11A erythroid-specific enhancer.Approximately 80% of the alleles at this locus were modified, with no evidence of off-target editing.After undergoing myeloablation, two patients -one with TDT and the other with SCD -received autologous CD34+ cells edited with CRISPR-Cas9 targeting the same BCL11A enhancer.More than a year later, both patients had high levels of allelic editing in bone marrow and blood, increases in fetal hemoglobin that were distributed pancellularly, transfusion independence, and (in the patient with SCD) elimination of vaso-occlusive episodes.(Funded by CRISPR Therapeutics and Vertex Pharmaceuticals; ClinicalTrials.govnumbers, NCT03655678 for CLIMB THAL-111 and NCT03745287 for CLIMB SCD-121.)T ransfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) are the most common monogenic diseases worldwide, with an annual diagnosis in approximately 60,000 patients with TDT and 300,000 patients with SCD.[1][2][3] Both diseases are caused by mutations in the hemoglobin β subunit gene (HBB).Mutations in HBB that cause TDT 4 result in reduced (β + ) or absent (β 0 ) β-globin synthesis and an imbalance between the α-like and β-like globin (e.g., β, γ, and δ) chains of hemoglobin, which causes ineffective erythropoiesis.5,6 Sickle hemoglobin is the result of a point mutation in HBB that replaces glutamic acid with valine at amino acid position 6.Polymerization of deoxygenated sickle hemoglobin causes erythrocyte deformation, hemolysis, anemia, painful vaso-occlusive episodes, irreversible end-organ damage, and a reduced life expectancy.5 Treatment options primarily consist of transfusion and iron chelation in patients with TDT 7 and pain management, transfusion, and hydroxyurea in those with SCD. 8 Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.Allogeneic bone marrow transplantation can cure both TDT and CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
23 Own result · 7 Partly supported · 5 Own interpretation · 4 Supported · 2 Supported so far · 2 Own method · 1 No full text of the sources · 1 Not checked yet · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genomewide association studies have identified single-nucleotide polymorphisms (SNPs) associated with increased expression of fetal hemoglobin in adults.26”
What the sources say
- Supportedcites [26] 26. Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemo- globin level. Science 2013; 342: 253-7. source
The paper states that GWAS identified variants at BCL11A associated with fetal hemoglobin (HbF) level. It also reports a common variant associated with elevated HbF, supporting the citing sentence’s summary (Abstract; page not provided). (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients with TDT or SCD who co-inherit hereditary persistence of fetal hemoglobin, in which fetal expression continues into adulthood, have little or no disease.25”
What the sources say
- Partly supportedcites [25] 25. Steinberg MH. Fetal hemoglobin in sickle cell anemia. Blood 2020; 136: 2392- 400. sourceExperimental — accuracy not yet measured
The “F-cells: heterogeneity of HbF concentrations” section reports that people with HbS-HPFH usually have no symptoms or hemolytic anemia, supporting the SCD part of the claim. It does not establish the same outcome for patients with transfusion-dependent thalassemia (TDT), so the claim extends beyond the source. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.”
What the sources say
- Supportedcites [10] 10. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2017; 376: 429-39. source
The Discussion reports a significantly lower frequency of sickle cell–related pain crises with crizanlizumab than with placebo in patients with SCD. This supports the attributed reduction in vaso-occlusive episodes; the cited paper reports the benefit for high-dose crizanlizumab. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Some of these SNPs are located in the BCL11A locus on chromosome 2 and are associated with a lower severity of both TDT and SCD.27”
What the sources say
- Partly supportedcites [27] 27. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phe- notype of β-thalassemia. Proc Natl Acad Sci U S A 2008; 105: 1620-5. sourceExperimental — accuracy not yet measured
The Results (page unavailable) place rs11886868 in BCL11A on chromosome 2 and find its C allele more frequent in milder, largely non-transfusion-dependent thalassemia intermedia than in transfusion-dependent thalassemia major. For SCD, the Discussion (page unavailable) reports an association with HbF levels, but says that using the variant to predict disease severity requires future study. The paper therefore does not establish lower severity within TDT or SCD. (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“BCL11A is a transcription factor that represses γ-globin expression and fetal hemoglobin in erythroid cells.”
What the sources say
- Supportedcites [1] 1. Bauer DE, Orkin SH. Hemoglobin switching's surprise: the versatile tran- scription factor BCL11A is a master re- pressor of fetal hemoglobin. Curr Opin Genet Dev 2015; 33: 62-70. source
The Genetic evidence connecting BCL11A and HbF regulation section identifies BCL11A as a transcriptional repressor and reports that its knockdown in human erythroid precursors leads to fetal hemoglobin expression. It also describes BCL11A's repression of γ-globin; the claim does not imply that BCL11A binds the γ-globin genes directly. (LLM, conf=0.94)
- Supportedcites [23] 23. Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med 2013; 3(1): a011643. source
In “Early Molecular Studies Lead to Therapeutic Approaches for HbF Induction,” the paper reports that BCL11A knockdown robustly induces γ-globin in primary adult erythroid progenitors. The same section describes BCL11A as a transcriptional regulator that functions to silence HbF. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Elevated levels of fetal hemoglobin (consisting of two alpha and two gamma chains) are associated with improved morbidity and mortality in patients with TDT and SCD.[20][21][22]”
What the sources say
- Partly supportedcites [20] 20. Musallam KM, Sankaran VG, Cappel- lini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood 2012; 119: 364-7. sourceExperimental — accuracy not yet measured
The Introduction reports that HbF modifies morbidity and mortality in adults with sickle cell disease. The Abstract and Results and discussion find lower morbidity with higher HbF in untransfused patients with β-thalassemia intermedia, not transfusion-dependent thalassemia (TDT); the study does not establish a mortality association in TDT. Passage-level page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [21] 21. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expec- tancy and risk factors for early death. N Engl J Med 1994; 330: 1639-44. sourceExperimental — accuracy not yet measured
The Risk Factors for Early Death section (p. 4) links higher fetal hemoglobin to lower mortality in patients with sickle cell anemia, and the Discussion (p. 6) reports improved life expectancy. The paper does not establish that association for transfusion-dependent thalassemia (TDT), or link fetal hemoglobin levels to improved morbidity. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [22] 22. Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates mor- bidity in sickle cell anemia? Blood 1984; 63: 921-6. source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“As a product that is enriched with CD34+ cells, CTX001 may have contributed to the delay in lymphocyte recovery, similar to what has been observed after T-cell-depleted transplantation.33,34”
What the sources say
- Supportedcites [33] 33. Bomberger C, Singh-Jairam M, Rodey G, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic pro- genitors. Blood 1998; 91: 2588-600. source
The paper’s Discussion (page unavailable) reports delayed quantitative lymphocyte recovery after transplantation with FACS-sorted CD34+ cells compared with conventional PBSC autografts. It also says sorting substantially depleted T cells, supporting the citing sentence’s qualified analogy to T-cell-depleted transplantation. The paper does not study CTX001, and the citing sentence does not claim that it does. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [34] 34. Nachbaur D, Kropshofer G, Heitger A, et al. Phenotypic and functional lympho- cyte recovery after CD34+-enriched versus non-T cell-depleted autologous peripheral blood stem cell transplantation. J Hema- tother Stem Cell Res 2000; 9: 727-36. source
hedgedconditionalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Levels of fetal hemoglobin increased rapidly from 0.3 g per deciliter at baseline to 8.4 g per deciliter at month 3, 12.4 g per deciliter at month 12, and 13.1 g per deciliter at month 18 (Fig. 2A).”
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After the administration of CTX001, high levels of edited alleles in bone marrow CD34+ cells and nucleated peripheral-blood cells were maintained (Table 1).”
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After the administration of CTX001 and over time, high levels of edited alleles in bone marrow CD34+ cells and nucleated peripheral-blood cells were maintained (Table 1).”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 18
- The quote only partly states this claim. 2
Every source the paper cites for this claim was checked and supports it.
In the paper
“The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease system, a bacterial immune system that can cleave bacteriophage or plasmid DNA, enables programmable targeting of insertions or deletions (indels) at a specific genomic DNA site.28,29”
What the sources say
- Supportedcites [28] 28. Bak RO, Dever DP, Porteus MH. CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nat Protoc 2018; 13: 358-76. sourceExperimental — accuracy not yet measured
The Introduction explains that an sgRNA guides Cas9 to a chosen DNA sequence, where a locus-specific break can be made. It also explains that repair of such breaks can produce insertions or deletions at the break site. Together, these passages support programmable targeting of indels, though indels are a possible repair outcome rather than a guaranteed one. (LLM, conf=0.92)
- Supportedcites [29] 29. Hendel A, Bak RO, Clark JT, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human pri- mary cells. Nat Biotechnol 2015; 33: 985-9. sourceExperimental — accuracy not yet measured
The paper’s introductory passage (indexed as Abstract; page unavailable) explains that guide RNA directs Cas9 to a chosen genomic DNA sequence and that repair of the resulting break can create insertions or deletions at that site. Its reported experiments also measure targeted indels at specific loci. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Betibeglogene autotemcel, a lentiviral vector-based gene-addition product, is approved in the European Union for the treatment of patients with TDT who have non-β 0 mutations and who do not have a matched sibling donor 14 and is being studied in patients with β 0 /β 0 TDT genotypes and in those with SCD.15,16”
What the sources say
- Not matchedcites [14] 14. European Medicines Agency. Zynteglo: summary of product characteristics (https:// www . ema . europa . eu/ en/ documents/ product -information/ zynteglo -epar -product -information_en . pdf).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites [15] 15. Thompson AA, Walters MC, Kwiat- kowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med 2018; 378: 1479-93. source
The β0/β0 TDT study clause is supported: the Methods describe two phase 1–2 studies of LentiGlobin BB305, and the patient-characteristics table includes participants with β0/β0 genotypes. The separate EU-approval clause is attached to citation 14, not to the citation for this study. (LLM, conf=0.91)
- Partly supportedcites [16] 16. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med 2017; 376: 848-55. sourceExperimental — accuracy not yet measured
The Discussion reports ongoing studies of the BB305 vector in patients with sickle cell disease and β-thalassemia. It also identifies four recipients as having transfusion-dependent β-thalassemia, but does not specify a β0/β0 genotype. The EU approval statement is attached to a different citation in the citing sentence and is not judged here. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“an erythroid-specific knockdown of BCL11A delivered by a lentiviral-encoded, microRNA-adapted short hairpin RNA molecule has been shown to reactivate the γ-globin gene and is in early clinical development.[17][18][19]”
What the sources say
- Partly supportedcites [17] 17. Brendel C, Guda S, Renella R, et al. Lineage-specific BCL11A knockdown cir- cumvents toxicities and reverses sickle phenotype. J Clin Invest 2016; 126: 3868- 78. sourceExperimental — accuracy not yet measured
The Results (pp. 4, 6) describe a lentiviral, erythroid-specific BCL11A shRNA-miR vector that induces γ-globin. But the paper calls its findings preclinical (Discussion, p. 8) and says they form the basis for a clinical trial application (p. 1); it does not establish that this approach was already in clinical development. (LLM, conf=0.85)
- Supportedcites [18] 18. Brendel C, Negre O, Rothe M, et al. Preclinical evaluation of a novel lentiviral vector driving lineage-specific BCL11A knockdown for sickle cell gene therapy. Mol Ther Methods Clin Dev 2020; 17: 589- 600. source
The Discussion states that erythroid-specific BCL11A knockdown using a lentiviral shRNAmiR reactivates γ-globin. It also identifies an ongoing pilot and feasibility clinical trial using this approach (NCT03282656). (LLM, conf=0.94)
- Supportedcites [19] 19. Esrick EB, Lehmann LE, Biffi A, et al. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med 2021;384:205-15. source
The Methods describe an open-label pilot study using a lentiviral vector encoding a microRNA-embedded shRNA for erythroid-specific BCL11A knockdown. The Discussion says this approach allows transcription of the endogenous γ-globin gene, supporting both the reactivation and early clinical-development parts of the claim. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.”
What the sources say
- Not checked — no full text of the sourcecites [9] 9. Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia. N Engl J Med 2020; 382: 1219-31. source
- Supportedcites [10] 10. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2017; 376: 429-39. source
For crizanlizumab, the Discussion reports a 45.3% lower annual pain-crisis rate than placebo, not elimination of crises. It also reports no significant change in markers of hemolysis, while the paper describes crizanlizumab as a P-selectin inhibitor. Together, these passages support that it does not address the underlying cause or fully ameliorate sickle cell disease; this citation does not establish the claim about luspatercept. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Neonates and infants with TDT or SCD are typically asymptomatic while their fetal hemoglobin levels remain high and become symptomatic during the first year of life when the synthesis of fetal hemoglobin declines 23,24 (Fig. 1A).”
What the sources say
- Partly supportedcites [23] 23. Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med 2013; 3(1): a011643. sourceExperimental — accuracy not yet measured
In “THE FETAL-TO-ADULT GLOBIN SWITCH” (page not provided), the paper says infants with β-thalassemia begin to show symptoms as HbF declines in the months after birth. It also links elevated HbF to an asymptomatic period in SCD, but says symptoms appear after infancy rather than during the first year; it discusses β-thalassemia generally, not TDT specifically. (LLM, conf=0.86)
- Partly supportedcites [24] 24. Canver MC, Orkin SH. Customizing the genome as therapy for the β-hemo- globinopathies. Blood 2016; 127: 2536- 45. sourceExperimental — accuracy not yet measured
The Introduction (page not provided) says fetal hemoglobin is silenced in the months after birth and protects against disease severity in β-globin disorders, including SCD and β-thalassemia. It does not say that infants with TDT or SCD are typically asymptomatic while HbF is high or that they become symptomatic during the first year as it falls. (LLM, conf=0.85)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the SNPs that are associated with fetal hemoglobin are in an erythroid-specific enhancer, downregulate BCL11A expression, and increase the expression of fetal hemoglobin.1,23”
What the sources say
- Supportedcites [1] 1. Bauer DE, Orkin SH. Hemoglobin switching's surprise: the versatile tran- scription factor BCL11A is a master re- pressor of fetal hemoglobin. Curr Opin Genet Dev 2015; 33: 62-70. source
In “Effects of common genetic variation on BCL11A,” the review places HbF-associated variants in an erythroid enhancer and reports that rs1427407 is associated with reduced BCL11A expression in human erythroid precursors. “Genetic evidence connecting BCL11A and HbF regulation” describes BCL11A as an HbF repressor and reports that reducing it permits HbF expression. Together, these passages support the claimed direction of effect. (LLM, conf=0.90)
- Partly supportedcites [23] 23. Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med 2013; 3(1): a011643. sourceExperimental — accuracy not yet measured
The section on early molecular studies reports that variants within BCL11A are associated with HbF levels and that experimentally knocking down BCL11A induces γ-globin expression. It does not say those SNPs lie in an erythroid-specific enhancer or establish that the SNPs themselves lower BCL11A expression and thereby raise HbF. (LLM, conf=0.87)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“During the 21.5 months after receiving CTX001, Patient 1 had 32 adverse events, most of which were considered to be grade 1 or 2 in severity (Table S6).Study investigators classified 2 adverse events as serious: pneumonia in the presence of neutropenia and veno-occlusive liver disease with sinusoidal obstruction syndrome (VOD-SOS), both of which began on study day 13.”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient received her last transfusion of packed red cells 30 days after the CTX001 infusion (Fig. 2C).”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“F-cell expression increased from 10.1% at baseline to 99.7% at month 6 and was maintained through month 18 (Fig. 2B).”
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patient 1 was a 19-year-old female with the β 0 /β + (IVS-I-110) genotype of TDT.Before enrollment, she had received 34 units of packed red cells per year, annualized over a 2-year period.”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In immunocompromised mice, there was equivalent engraftment for control and single-guide RNA-edited cells, and the persistence and pattern of edits were stable at 16 weeks, with maintenance of the diversity of edits (Tables S2 and S3 and Fig. S1 in the Supplementary Appendix).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patient 2 was a 33-year-old female with SCD (βS/ βS and a single α-globin deletion).In the 2 years before enrollment, she had averaged seven severe vaso-occlusive episodes per year.”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, the fetal hemoglobin level was 9.1% and the sickle hemoglobin level was 74.1%.At month 3, the fetal hemoglobin level rose to 37.2% and the sickle hemoglobin level was 32.6%.At month 15, the fetal hemoglobin level rose to 43.2% and the sickle hemoglobin increased to 52.3% (Fig. 2D).”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“High frequencies of allelic editing (mean [±SD], 80±6%) were observed and maintained across all subpopulations of CD34+ cells, including long-term hematopoietic stem cells.”
plainn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CTX001 drug product had an allelic editing frequency of 68.9%.”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Four other enrolled patients with SCD withdrew from the study before being treated with CTX001 (Table S16).”
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patient 2 had 114 adverse events during the 16.6 months after receipt of the CTX001 infusion (Table S11).Study investigators classified 3 adverse events as serious: sepsis in the presence of neutropenia (on day 16), cholelithiasis (on day 49), and abdominal pain (on day 56).All 3 adverse events resolved with treatment.”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patient 2 had no vaso-occlusive episodes during the 16.6 months after the infusion of CTX001, and the last transfusion of packed red cells was 19 days after infusion (Fig. 2F).”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Without CTX001, the patients' pre-enrollment disease severity would have continued, making pre-enrollment rates a valid comparator.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“F-cell expression was 99.9% at month 5 and was maintained at nearly 100% through month 15, her most recent study visit (Fig. 2E).”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Study investigators observed intermittent, nonserious lymphopenia, which they considered to be probably due to a delay in T-cell recovery after the infusion of CTX001 and which had resolved by study day 351.”
hedgedconditionalSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An additional limitation of our study is that although we performed comprehensive preclinical on-target and off-target analyses and assays of erythrocyte differentiation, we have not performed similar analyses on clinical samples nor characterized their clonal diversity.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study sponsors (CRISPR Therapeutics and Vertex Pharmaceuticals) designed the study protocols, with oversight provided by the study steering committees and an independent data monitoring committee.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Initial results from the follow-up of the first two patients who were treated with CTX001 have shown the intended CRISPR-Cas9 editing of BCL11A in long-term hematopoietic stem cells, with durable engraftment, high levels of fetal hemoglobin expression, and the elimination of vaso-occlusive episodes or need for transfusion.”
plaindirectn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The clinical improvements after CTX001 are attributable to the gene editing rather than to other aspects of treatment or disease fluctuation.
- Rests on an assumption: Long-term maintenance of edited alleles in peripheral blood reflects editing of long-term hematopoietic stem cells.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The generalizability of these early results with respect to other patients with TDT and SCD remains to be determined.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper relies on this without support.
Erythrocytes with high fetal hemoglobin have a survival advantage.
“consistent with an expected survival advantage of erythrocytes with a high level of fetal hemoglobin.”
The paper relies on this without support.
Without CTX001, the patients' pre-enrollment disease severity would have continued, making pre-enrollment rates a valid comparator.
“Before enrollment, she had received 34 units of packed red cells per year, annualized over a 2-year period.”
“In the 2 years before enrollment, she had averaged seven severe vaso-occlusive episodes per year.”
The paper relies on this without support.
The clinical improvements after CTX001 are attributable to the gene editing rather than to other aspects of treatment or disease fluctuation.
“The clinical course of both patients supports our conclusion that CTX001 mimics the phenotype of hereditary persistence of fetal hemoglobin levels.”
The paper relies on this without support.
Long-term maintenance of edited alleles in peripheral blood reflects editing of long-term hematopoietic stem cells.
“Initial results from the follow-up of the first two patients who were treated with CTX001 have shown the intended CRISPR-Cas9 editing of BCL11A in long-term hematopoietic stem cells, with durable engraftment, high levels of fetal hemoglobin expression, and the elimination of vaso-occlusive episodes or need for transfusion.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“CRISPR/Cas-9 for targeted sickle cell disease (SCD) therapy and β-thalassemia have been also applied in clinical trials.23”
From Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing (2021) · cites this paper as [23]
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Self-citationPiel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Self-citationChemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
Crizanlizumab for the prevention of pain crises in sickle cell disease.
Ataga, K. I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., Guthrie, T. H., Knight-Madden, J., Alvarez, O. A., Gordeuk, V. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611770 · Cited by 914
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
Cao, A., & Galanello, R. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cd68ed · Cited by 722
Gene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696
Self-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationUda, M., Galanello, R., Sanna, S., Lettre, G., Sankaran, V. G., Chen, W., Usala, G., Busonero, F., Maschio, A., Albai, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711566105 · Cited by 672
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
Cited by
Sorted by citations
Items 1,101–1,200 of 1,950
How the gene-editing in medicine and public health practice could stand the test of bioethics
Zang, Z., & Chen, Y. (2021) · Acta bioethica · doi:10.4067/s1726-569x2021000100049 · Cited by 4
Self-citationProspects for Stem Cell-Based Regenerative Therapies in India
Boopalan, D., Pandian, R., & Kesavan, G. (2021) · StemJournal · doi:10.3233/stj-210002 · Cited by 5
“Recent advances in gene editing technologies like CRISPR, and the recent demonstration of CRISPRedited BCL11A gene in autologous HSCs, have opened possibilities to autologously treat thalassemia using a patient’s own cells [6].”
Cannon, P. M., & Kiem, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.016 · Cited by 4
The CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective
Lattanzi, A., & Maddalo, D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0002 · Cited by 4
Precise somatic genome editing for treatment of inborn errors of immunity
Meng, Q., Sun, H., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.960348 · Cited by 4
Diagnostik und Therapie der alpha- und beta-Thalassämien
Cario, H. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1767-8379 · Cited by 4
Hulbert, M. L., King, A. A., & Shenoy, S. S. (2022) · Hematology · doi:10.1182/hematology.2022000372 · Cited by 4
Gene Therapy and Its Applications
Bansal, A., Prakash, R., Agarwal, S., & Advani, U. (2023) · Journal of Medical Evidence · doi:10.4103/jme.jme_65_21 · Cited by 5
Engineering of the endogenous HBD promoter increases HbA2
Boontanrart, M. Y., Mächler, E., Ponta, S., Nelis, J. C., Preiano, V. G., & Corn, J. E. (2023) · eLife · doi:10.7554/elife.85258 · Cited by 4
“On-going On-going clinical trials re-express HbF to extremely high levels not commonly seen even in individuals with Hereditary Persistence of Fetal Hemoglobin Frangoul et al., 2021 .”
Mendelson, A., Liu, Y., Bao, W., & Shi, P. A. (2024) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2024.102824 · Cited by 5
Klink, M., Felber, M., Zeilhofer, U., Hauri-Hohl, M. M., Schmugge, M., Drozdov, D., & Güngör, T. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.30988 · Cited by 4
“7 10 Genetherapyapproachesareinadvanceddevelopment, 11–13 and are increasingly available in more and more centers worldwide.”
BackgroundYi, H., Yun, Y., Choi, W. H., Hwang, H.-Y., Cha, J. H., Seok, H., Song, J., Lee, J. H., Oh, S. H., Lee, S.-Y., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102199 · Cited by 5
Vadolas, J., Nualkaew, T., Voon, H. P. J., Vilcassim, S., & Grigoriadis, G. (2024) · HemaSphere · doi:10.1002/hem3.78 · Cited by 5
A new breakthrough in genome editing: the story of Casgevy
Olalla-Sastre, B., & Rı́o, P. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.06.003 · Cited by 4
Filling the Gap Until Full Vaccine Deployment in the War on Coronavirus Disease-19
Mattoli, S. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00394-3 · Cited by 4
CRISPR Hits Home in a First-in-Human Study
Musunuru, K. (2021) · The CRISPR Journal · doi:10.1089/crispr.2021.29131.mus · Cited by 4
Holdreith, N., Lee, G., Chandra, V., Salinas, C. S., Nicholas, P., Olson, T. S., & Tong, W. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004205 · Cited by 5
CRISPR-Click Enables Dual-Gene Editing with Modular Synthetic sgRNAs
Park, H., Osman, E. A., Cromwell, C. R., Laurent, C. D. S., Liu, Y., Kitova, E. N., Klassen, J. S., Hubbard, B. P., Macauley, M. S., & Gibbs, J. M. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00106 · Cited by 4
Review: RNA-Based Diagnostic Markers Discovery and Therapeutic Targets Development in CancerPreprint
Wang, H., Meng, Q., Qian, J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3975297 · Cited by 4
Sckaff, M., Gill, K., Sachdev, A., Birk, A. M., Arogundade, O. A., Watry, H., Keough, K. C., Tsai, Y.-C., Ziegle, J. S., Conklin, B. R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.21.492887 · Cited by 4
Lentiviral Vectors for Gene Therapy
Wang, X., & He, Z. (2022) · Wiley eBooks · doi:10.1002/9780470015902.a0029449 · Cited by 4
Hara, Y., Kawabata, E., Lemgart, V. T., Bronson, P. G., Hicks, A., Peters, R., Krishnamoorthy, S., Ribeil, J., Schmunk, L. J., Eglinton, J., et al. (2023) · medRxiv · doi:10.1101/2023.03.14.23287244 · Cited by 4
Maroofi, N., Maleki, M. S. M., Tahmasebi, M., Khorshid, H. R. K., Modaberi, Y., Najafipour, R., & Banan, M. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01155-0 · Cited by 3
“This specific GATA1 site has since been targeted by CRISPR/ Cas9 for the treatment of TDT and SCD patients [2–5].”
InfluentialErlich, H. A., Ko, L., Lee, J., Eaton, K., Calloway, C., Lal, A., Das, R., Jamwal, M., López-Peña, C., & Mack, S. J. (2024) · Croatian Medical Journal · doi:10.3325/cmj.2024.65.180 · Cited by 3
Quantifying the unique mechanical properties of irreversibly sickled cells in sickle cell disease
Williams, D. C., Higgins, J. M., & Wood, D. K. (2025) · Blood Vessels Thrombosis & Hemostasis · doi:10.1016/j.bvth.2025.100077 · Cited by 3
CRISPR/Cas in dermatology: A scoping review of candidate diseases for clinical applications
Hwang, J. C., Brown, R., Ha, E. K., & Tung, J. K. (2025) · JAAD reviews. · doi:10.1016/j.jdrv.2025.05.003 · Cited by 3
Modi, N., Guo, J. Z., Lee, R., Greenstein, A., & Lee, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125643 · Cited by 3
“However, CRISPR-based therapies are now on the horizon for the treatment of debilitating diseases such as sickle cell disease [19], cancer [20], and, most recently, a rare condition called carbamoyl phosphate synthase 1 (CPS1) deficiency [21].”
Detection of pre-existing immunity to bacterial Cas9 proteins in people with cystic fibrosis
Serpa, G., Gong, Q., De, M., Rana, P. S. J. B., Montgomery, C. P., Wozniak, D. J., Long, M. E., & Hemann, E. A. (2025) · ImmunoHorizons · doi:10.1093/immhor/vlaf041 · Cited by 3
Krishnamurti, L., Olafimihan, A. G., & Hsu, L. L.-Y. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017015 · Cited by 4
Doherty-Boyd, W. S., Tsimbouri, P. M., Jayawarna, V., Walker, M., Taqi, A. F., Mahon, N., Meek, R. M. D., Young, P. S., Miller, A. F., West, A. G., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123803 · Cited by 3
Engineering with care: safety assessment platforms for CRISPR-modified natural killer cells
Fazeli, A., Ullrich, E., Cathomen, T., & Bexte, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1711414 · Cited by 3
Jin, B., Kumari, T., Lee, J., Kim, J.-S., Bokorová, R., Gheware, A., Ripoll, C. V., Sargazi, A., Jeong, S., Hyun, Y., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag003 · Cited by 4
Eze, V. H. U., Eze, C. E., Alaneme, G. U., Mirembe, N. F., Ugwu, O. P.-C., Ogenyi, F. C., Ugwu, C. N., Okon, M. B., & Ugwu, J. N. (2026) · Frontiers in Nanotechnology · doi:10.3389/fnano.2025.1686599 · Cited by 6
“They can safeguard drugs from premature degradation, enhance cellular uptake, and exploit mechanisms such as the enhanced permeability and retention (EPR) effect to accumulate preferentially in diseased tissues (Suri et al., 2007; Frangoul et al., 2021).”
Shah, W., Hussain, M., Serwat, A., Bilal, M., Raza, Y., Mansoor, A., & Faraz, A. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.120875 · Cited by 4
Advances in Double‐Stranded DNA Targeting Technologies
Shen, Z., Liu, Y., Hao, Y., Bo, Y., Dai, X., Wang, S., Xia, T., Su, X., & Liu, H. (2026) · Exploration · doi:10.1002/exp.20250065 · Cited by 3
Wang, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1745975 · Cited by 3
Liu, S., Chen, Y., Li, Y., Qian, L., Dong, G., Zhang, Q., Zhou, X., Guo, H., Sun, H., Lin, Q., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.017 · Cited by 4
Self-citationLiu, R., Xiao, H., Qin, C., Hu, J., Luo, J., Chen, H., Zhang, X., Yin, X., Nai, G., Wang, G., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69756-8 · Cited by 3
“Gene therapy is rapidly emerging as a potentially curative treatment option for patients with TDT and SCD 25 – 27 .”
Functional decoupling of crRNA enables customizable CRISPR diagnostics
Park, H., Yun, J., Lee, K., Kim, J. H., Park, J.-H., Park, Y.-J., Park, J. H., Lee, H., & Kim, M.-G. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag189 · Cited by 3
“The clustered regularly interspaced short palindromic repeats (CRISPR) system, which has revolutionized biotechnology through applications in gene editing [ 1 –3 ], therapy [ 4 , 5 ], and imaging [ 6 , 7 ], has more recently expanded into diagnostics [ 8 –10 ].”
Dhara, C., Sah, H., Gantayat, S., Rajput, M., & Mishra, S. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11815-w · Cited by 4
Applications of genome editing technologies in the treatment of human diseases
Alshorman, J., Mehran, M. J., Tembo, K. M., Mostafavi, N., Bolideei, M., & Wang, Y. L. (2026) · Gene Therapy · doi:10.1038/s41434-026-00627-z · Cited by 3
A society-wide conversation is needed about germline genome editing using CRISPR
Birney, E. (2024) · Nature Medicine · doi:10.1038/s41591-023-02681-1 · Cited by 3
The Role of Genetics in Advancing Cardiometabolic Drug Development
Abou-Karam, R., Cheng, F., Gady, S., & Fahed, A. C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01195-6 · Cited by 3
“In clinical trials, the treatment resulted in independence from needing transfusion and resolution of vaso-occlusive pain crises [73, 78].”
Success in Sight for Gene Editing
Bainbridge, J. W. (2024) · New England Journal of Medicine · doi:10.1056/nejme2405256 · Cited by 3
Current and emerging drug treatment strategies to tackle sickle cell anemia
Persaud, Y., Leonard, A. K., & Rai, P. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2379260 · Cited by 3
Dutta, A., Dutta, T. S., Shukla, A., & Gogoi, P. (2024) · Cureus · doi:10.7759/cureus.74489 · Cited by 3
Ye, Y., Niu, C. S., Mao, A., Qin, L., Zhan, J., Chen, W., Liu, Z., Xie, T., Zhang, Q., Li, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202410992 · Cited by 4
Genetic suppression interactions are highly conserved across genetically diverse yeast isolates
Paltenghi, C., & van Leeuwen, J. S. (2025) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkaf047 · Cited by 3
Creating New Cis-Regulatory Elements of HBD to Reactivate Delta-Globin
Chen, L., Liu, D., Hong, W., Xu, L., Cheng, L., Luo, Y., Xu, H. M., Li, X., Fang, J., & Li, X. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.186 · Cited by 3
Takezaki, M., Li, Y., Xu, H., Patel, N., Lucas, R., Cerbone, R. E., Koti, S., Hendrick, C. L., Junker, L. H., & Pace, B. S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323550 · Cited by 3
“The first is Exa-cel, using CRISPR technology to disrupt an erythroid-specific enhancer in BCL11A , a significant repressor of γ -globin gene transcription [41,42].”
Gene therapy in neuronopathic lysosomal storage disorders
Donald, A., Horgan, C., López, M. J. D. C., Jones, S., & Wynn, R. F. (2025) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2025.05.010 · Cited by 6
Gibson, N. M., Elgarten, C. W., Oved, J. H., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.06.029 · Cited by 3
Self-citationBeyond transfusions and transplants: genomic innovations rewriting the narrative of thalassemia
Shi, L., Yan, X., Xia, Y., Zhao, Y., Zhu, X., Li, Q., & Xu, Z. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06548-y · Cited by 6
“However, clinical trial data on the direct editing of HPFH mutations is still limited, with most studies Table 3 Major transcriptional regulators that modulate gamma-globin expression of 82.6% and increased HbF levels by 43.2% [ 78 ].”
InfluentialIntegrating natural and engineered genetic variations to decode regulatory influence on blood traits
Tardáguila, M., Schiller, D. V., Colombo, M., Gori, I., Coomber, E. L., Vanderstichele, T., Benaglio, P., Chiereghin, C., Gerety, S. S., Vuckovic, D., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116937 · Cited by 3
Designing genome editing experiments with EditABLE
Maxim, D. S., Sostena, J., Johnson, N. S., et al. (2026) · Genome biology · doi:10.1186/s13059-026-04095-x · Cited by 3
“EditABLE will facilitate the development of targeted gene editing therapies for multiple genetic diseases, building off existing gene editing clinical trials in humans [1, 20, 21].”
Cost of home vs clinic administration of paclitaxel in metastatic breast cancer
Sharma, D. (2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88563 · Cited by 5
Jones, J. C., Bassett, G. M., Lescalleet, J. L., & Wingert, J. R. (2021) · Journal of Biological Education · doi:10.1080/00219266.2021.1909640 · Cited by 3
“Additionally, there are several recent reports of successful and safe somatic gene editing experiments in humans (Frangoul et al. 2021; Stadtmauer et al. 2020; Wu et al. 2019).”
BackgroundTargeting ZNF410 as a potential β-hemoglobinopathy therapy
Tumburu, L., & Thein, S. L. (2021) · Nature Genetics · doi:10.1038/s41588-021-00817-y · Cited by 3
Bringing gene therapy to where it’s needed
Radtke, S., & Kiem, H. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.01.005 · Cited by 3
A CRISPR-p53 interactome with potential implications for clinical CRISPR/Cas9 use
Jiang, L., & Wermeling, F. (2022) · Oncoscience · doi:10.18632/oncoscience.557 · Cited by 3
CRISPR Targeting the Integrated HTLV-1 Virus
Wilkie, T., & Panfil, A. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-93333-3_6 · Cited by 3
Li, M., Morse, B. A., & Kassim, S. H. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2101361 · Cited by 4
“For example, development of an ex vivo delivered CRISPR/Cas9 edited HSPC necessitates GMP manufacturing oversight of the drug product, enzyme, and gRNA.”
BackgroundInfluentialEpigenetics: Science of Changes without Change in DNA Sequences
Dhargawe, J., Lakkakul, R., & Hirapure, P. (2022) · Biochemistry · doi:10.5772/intechopen.105039 · Cited by 3
The Utilization of CRISPR/Cas9 in Monogenic Disorders Authors
Mellor, S. M. (2022) · Spectra Undergraduate Research Journal · doi:10.9741/2766-7227.1018 · Cited by 3
Perspectives and challenges to discovering hemoglobin-inducing agents in Sickle Cell Disease
Pavan, A. R., Lopes, J. R., Imperador, C. H. L., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1002063 · Cited by 3
Liu, Y., Xing, K., Wu, Z., et al. (2022) · Aquaculture Reports · doi:10.1016/j.aqrep.2022.101366 · Cited by 3
The basics of blood and associated disorders
Ashwell, E. (2022) · British Journal of Nursing · doi:10.12968/bjon.2022.31.21.1096 · Cited by 3
An Overview of Gene Editing Modalities and Related Non-clinical Testing Considerations
Vats, S., Ballesteros, C., Hung, S., Sparapani, S., Wong, K., Haruna, J., Li, C., & Authier, S. (2023) · International Journal of Toxicology · doi:10.1177/10915818231153996 · Cited by 4
Nonviral Ex Vivo Genome Editing in Mouse Bona Fide Hematopoietic Stem Cells with CRISPR/Cas9
Hara, H., Natsagdorj, M., Byambaa, S., & Hanazono, Y. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3016-7_16 · Cited by 4
Wang, L., Siwko, S. K., & Li, D. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad009 · Cited by 3
“In the past 2 years, sporadic clinical results have shed light on CRISPR technology’s effectiveness and safety [1], encouraging researchers to invest more effort in these types of translational studies.”
To Mars and Beyond: Engineering Life as a Moral Duty
Mason, C. E. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.29094.cma · Cited by 3
Muto, V., Benigni, F., Magliocca, V., Borghi, R., Flex, E., Pallottini, V., Rosa, A., Compagnucci, C., & Tartaglia, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097988 · Cited by 3
“Recently, the same technology in human progenitor cells (HSPCs) has been applied as a precise genome editing tool for treating beta-thalassemia and sickle cell disease [39].”
MethodFañanas-Baquero, S., Morin, M., Fernández, S., Ojeda-Pérez, I., Dessy-Rodríguez, M., Giurgiu, M., Bueren, J. A., Moreno-Pelayo, M. Á., Segovia, J. C., & Bustamante, O. Q. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1104666 · Cited by 3
“On the other hand, the reexpression of fetal globins by gene editing is a true therapeutic alternative for the treatment of β-thalassemia and sickle cell disease (Canver et al., 2015; Brendel et al., 2016; Ye et al., 2016; Lux et al., 2019; Frangoul et al., 2021; Fu et al., 2022).”
Background“Severity” in adult sickle cell disease
Steinberg, M. H., & Gladwin, M. T. (2023) · American Journal of Hematology · doi:10.1002/ajh.27024 · Cited by 3
Self-citationA new beginning: can omidubicel emerge as the next, viable alternative donor source?
Gandhi, A. P., Newell, L. F., & Maziarz, R. T. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231192146 · Cited by 3
The incredible ULK improves β-thalassemia
Babbs, C. (2023) · Blood · doi:10.1182/blood.2023021369 · Cited by 3
Mathews, D., Abernethy, A. P., Verily, Chaikof, E. L., Charo, R. A., Daley, G. Q., Enriquez, J., Management, E. V., Gottlieb, S., Associates, N. E., et al. (2023) · NAM Perspectives · doi:10.31478/202311d · Cited by 4
Gene-addition/editing therapy in sickle cell disease
Pollock, G., Nègre, O., & Ribeil, J. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104214 · Cited by 3
Recent advances in hematopoietic gene therapy for genetic disorders
Galy, A. H. M., & Dewannieux, M. (2023) · Archives de Pédiatrie · doi:10.1016/s0929-693x(23)00224-5 · Cited by 3
CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis
Panichella, G., & Aimo, A. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128267417231127070901 · Cited by 3
Curative Therapies for Sickle Cell Disease
Kaviany, S., Barnawi, Z., & LaBelle, J. L. (2024) · Pediatric Annals · doi:10.3928/19382359-20231205-06 · Cited by 3
Characterization of NiCas12b for In Vivo Genome Editing
Zhang, Y., Wei, J., Wang, H., & Wang, Y. (2024) · Advanced Science · doi:10.1002/advs.202400469 · Cited by 3
Genome-wide methylation and gene-expression analyses in thalassemia
Zhang, W., Li, X., Yu, U., Huang, X., Wang, H., Lu, Y., Liu, S., & Zhang, J. (2024) · Aging · doi:10.18632/aging.206037 · Cited by 3
The Pharmaceutical Year that was, 2024
Fox, A. W. (2024) · Pharmaceutical Medicine · doi:10.1007/s40290-024-00540-z · Cited by 3
“These endpoints were achieved in > 95% treated patients [2].”
Yang, J.-P., Toughiri, R., Gounder, A. P., Scheibe, D., Petrus, M. J., Fink, S. J., Vallée, S., Kenniston, J. A., Papaioannou, N., Langston, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307049 · Cited by 5
DNA regulatory element cooperation and competition in transcription
Lee, H., Friedman, M. J., Kim, S. B., & Oh, S. (2024) · BMB Reports · doi:10.5483/bmbrep.2024-0069 · Cited by 4
“As noted above, restoring HbF production in adult erythroid cells represents a viable treatment option for inherited hemoglobinopathies, such as -thalassemia and sickle cell disease (3, 87).”
Role of B-Cell Lymphoma/Leukemia 11A in Normal and Malignant Hematopoiesis
Zhang, H., Zeng, J., Zhang, F., Liu, J., & Liang, L. (2025) · Biology · doi:10.3390/biology14010026 · Cited by 4
AI learns from chromatin data to uncover gene interactions
Brożek, A., & Theodoris, C. V. (2025) · Nature · doi:10.1038/d41586-024-04107-5 · Cited by 3
Hyperactive deoxy-PIEZO1 shapes the circulatory life cycle of irreversibly sickled cells
Lew, V. L., & Rogers, S. D. (2025) · Biophysical Journal · doi:10.1016/j.bpj.2025.02.005 · Cited by 3
Human health and genetic technology
Dederer, H. (2025) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.12.006 · Cited by 4
Hematopoietic Stem Cell Transplantation in Sickle Cell Disease
Essa, M., Alzahrani, M., Alahmari, A. D., & Aljurf, M. D. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-84988-6_10 · Cited by 3
Li, G., Zhou, X., Zhu, G., Pan, Y., Yan, J., Meng, J., Ye, T., Cheng, Y., Liu, C., & Gu, Z. (2025) · Animals · doi:10.3390/ani15152161 · Cited by 3
“Additionally, PE could be used to introduce beneficial mutations in genes involved in disease resistance, similar to how it has been proposed for treating β -thalassemia in humans [95], thereby enhancing the prawn’s ability to withstand pathogen infections.”
Gene Therapy for Sickle Cell Anemia in India - Current Status and Challenges
Goel, A., Dalal, V., Dhawan, R., Maiti, S., & Chakraborty, D. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02105-9 · Cited by 4
Professionally Responsible Counseling About Fetal Analysis
Chervenak, F. A., & McCullough, L. B. (2021) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2021.06.005 · Cited by 3
Let's Get Back to Normal? COVID-19 and the Logic of Cure
Berghs, M. J. (2022) · Frontiers in Sociology · doi:10.3389/fsoc.2022.782582 · Cited by 3
“If we take “rare” diseases, such as, for example the inherited genetic blood disorders sickle cell and thalassaemia that affect millions of people worldwide, recent innovations in terms of therapies and curative genomic realities in gene editing (Frangoul et al., 2021) with “functional cures”, convey numerous difficul…”
BackgroundDowling, J. J. (2022) · Gene Therapy · doi:10.1038/s41434-022-00323-8 · Cited by 3
“, introducing Cas9 to cells and then re-introducing them to patients), such as was recently done for sickle cell disease and beta thalassemia [23], does not appear to induce an immune response.”
BackgroundGene Therapy and Cardiovascular Diseases
Lu, D., Cushman, S., Thum, T., & Bär, C. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_16 · Cited by 3
Lee, L., Gollen, R., Fathallah, A. M., Gao, L., & Patil, S. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2172 · Cited by 3
Consensus too soon: judges’ and lawyers’ views on genetic information use
Selita, F., Chapman, R., Kovas, Y. V., Smereczynska, V., Likhanov, M. V., & Toivainen, T. (2023) · New Genetics and Society · doi:10.1080/14636778.2023.2197583 · Cited by 4
“These fast-developing technologies have already led to signi fi cant developments in medicine and biology, with the fi rst clinical trials on human cells underway in many countries (Cyranoski 2016; Frangoul et al .”
BackgroundLeveraging microRNAs for cellular therapy
Hasiuk, M., Dölz, M., Marone, R., & Jeker, L. T. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.08.005 · Cited by 3
Metadata
- Authors
- Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., Ho, T. W., Kattamis, A., Kernytsky, A., Lekstrom-Himes, J., Li, A. M., Locatelli, F., Mapara, M. Y., de Montalembert, M., Rondelli, D., Sharma, A., Sheth, S., Soni, S., Steinberg, M. H., Wall, D., Yen, A., & Corbacioglu, S.
- Affiliations
- Boston University (US)
- From the Sarah Cannon Center for Blood Cancer at the Children’s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children’s Research Hospital, Memphis (A.S.) — both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) — both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Gesù Rome, Sapienza...
- ORCID
- Frangoul, Haydar
- Altshuler, David
- Cappellini, M. Domenica
- Chen, Yi-Shan
- Grupp, Stephan
- Handgretinger, Rupert
- Ho, Tony W.
- Kattamis, Antonis
- Lekstrom-Himes, Julie
- Li, Amanda M.
- Locatelli, Franco
- Mapara, Markus Y.
- Rondelli, Damiano
- Sharma, Akshay
- Sheth, Sujit
- Soni, Sandeep
- Steinberg, Martin H.
- Wall, Donna
- Corbacioglu, Selim
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-21
- Volume
- 384
- Issue
- 3
- Pages
- 252-260
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3112179900
- Semantic Scholar
- 07c69f7ddd34ca8c80618e16981e2fbdb0de6529
- Cited by
- 1,962
- References
- 35
- Citations by year
- 2026: 330 · 2025: 342 · 2024: 392 · 2023: 333 · 2022: 323 · 2021: 232
- FWCI
- 116.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Funders
- CRISPR Therapeutics AG
- Vertex Pharmaceuticals Incorporated
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- sickle cell disease, beta-thalassemia, CRISPR/Cas9 genome editing, fetal hemoglobin, hematopoietic stem cell transplantation, autologous hematopoietic stem cells, electroporation, transfusion independence, vaso-occlusive crisis
- MeSH terms
- Gene Editing, Adult, Anemia, Sickle Cell, Female, Fetal Hemoglobin, Humans, Repressor Proteins, Genetic Therapy, beta-Thalassemia, Young Adult, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
